clinicaltrials.gov/ct2/show/NCT00981695?term=MVA.HIVA+and+pedvacc&rank=1 The Pan African
Clinical Trials Registry (PACTR2009010001152787) http://www.pactr.org/ATMWeb/appmanager/atm/atmregistry?_nfpb=true&_windowLabel=basicSearch_1_2&basicSearch_1_2_actionOverride=%2Fpageflows%2Ftrial%2FbasicSearch%2FviewTrail&basicSearch_1_2id=115. “
“The majority of high income countries have GS-7340 purchase introduced three-dose routine human papillomavirus (HPV) vaccination programmes . Although most countries are vaccinating girls/women, only the US, Australia and one Canadian province (Prince Edward Island) have included boys in their routine HPV vaccination programmes. The most commonly used HPV vaccine in high
income countries (including Canada, the UK, the US and Australia) Everolimus solubility dmso is the quadrivalent , which protects against HPV-16/18 (responsible for more than 70% of cervical cancers  and associated with other anogenital  and  and head and neck cancers ) and HPV-6/11 (associated with more than 85% of anogenital warts ). Although vaccinating girls against HPV is expected to dramatically reduce the burden of HPV-associated diseases  and  and to be highly cost-effective ,  and , it nevertheless imposes an important financial strain on immunisation budgets. In Canada, HPV vaccine represents 40% of the total cost to fully immunise a girl from infancy to adolescence (Dr. Bruno Turmel, Quebec Ministry of Health and Social Services, Personal communication) . Decision-makers may thus be interested in the possibility of reducing doses of HPV vaccine to invest the funds on improving coverage to underserved populations, male HPV vaccination or other immunisation programmes. Recent evidence suggests that two doses of HPV vaccine may be as protective as three doses in the short-term. A nested nonrandomised 4-Aminobutyrate aminotransferase analysis within a phase III randomised clinical trial in Costa Rica suggested that two doses of HPV vaccine has similar high efficacy against vaccine-type persistent
infections as three doses, four years after vaccination . More recently, a phase III randomised trial examined the immunogenicity of two doses in girls 9–13 years compared to three doses in girls 9–13 years and three doses among young women 16–26 years. Results from the study showed that antibody responses for the vaccine-types among girls (9–13 years) who received two doses were noninferior to those among young women (16–26 years) who received three doses, over a period of three years after the last vaccine dose . However, antibody responses to HPV-18 at two years and HPV-6 at three years were significantly lower for girls (9–13 years) who received two doses vs. girls (9–13 years) who received three doses.